Hydrogenology
Hydrogenology editorial study record

Effect of hydrogen gas inhalation on T lymphocyte subsets in infectious mononucleosis

Liu H, Song S, Li J, Liu S, Yan J, Yan J, Li L, Li N, Wang P, Yin X, Wei Y, Lin A. · Adv Clin Med. 2021;11(10):4424–4430.

HumanInhaled H₂Published 2021
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized controlled parallel study

Research topic

Immune and inflammatory conditions

Administration classification

Inhaled H₂

Study result signal

Reported positive immune-cell signal with high uncertainty.

Outcome type

Symptoms, immune-cell laboratory outcomes and reported safety.

Reported in the source

Methods at a glance

Population or model

Children aged 1–10 years with infectious mononucleosis.

Sample

60 children; 30 per group.

Duration

10 days.

Intervention

Standard acyclovir and symptomatic care plus 66.7% H₂/33.3% O₂ inhalation.

Hydrogen form

Inhaled hydrogen–oxygen mixture.

H₂ specification

66.7% H₂ and 33.3% O₂ at 3 L/min for 60 minutes daily.

H₂ flow

3 L/min.

O₂ delivered with H₂

33.3% O₂ was co-delivered.

Comparator

Standard acyclovir and symptomatic care without the gas intervention.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Clinical symptoms, CD4 and CD8 lymphocyte subsets and adverse events.

Reported result

Both groups changed over time; reported changes in CD4, CD8 and CD4/CD8 ratios favored the gas-intervention group, with no obvious adverse events reported.

Results-extraction completeness

The full article methods, intervention, outcomes, positive and null findings, funding and conflict statements were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Single-center, unclear concealment and blinding, co-delivered oxygen and limited clinical-outcome reporting.

Applies directly to

Children with infectious mononucleosis receiving the stated standard care.

Preliminary appraisal framework

Cochrane RoB 2 — preliminary

Preliminary risk-of-bias status

High risk

Appraisal rationale

Random-number-table allocation was reported, but concealment, blinding and protocol-based outcome selection were not established; oxygen co-delivery complicates attribution.

Appraisal domains

Random sequence reported or described · Allocation concealment not fully established · Deviations and co-interventions checked · Outcome measurement checked by endpoint · No outcome-level protocol comparison completed

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

DOI: 10.12677/acm.2021.1110648 · DOI: 10.12677/acm.2021.1110648

Publisher access

A free publisher or repository full article was checked.

Extraction basis

Publisher or repository full article and bibliographic record; checked 10 August 2026.

Record revision

2026-08-10